6/29/23, 11:57 PM SWOG 8949 Pathway Feedback Search Clinical Topics Home Studies SWOG 8949 SWOG 8949 Disease Renal cell carcinoma Trial question Is radical nephrectomy followed by therapy with interferon alfa-2b superior to interferon alfa-2b therapy alone in patients with metastatic renal cell cancer? Study design Multi-center Open label RCT Population Characteristics of study participants 30.6% female N = 246 69.4% male 246 patients (74 female, 167 male) Inclusion criteria: patients with metastatic renal cell cancer who were acceptable candidates for nephrectomy Key exclusion criteria: thrombosis of the IVC below the hepatic veins, uncontrolled cardiac arrhythmias, prior treatment with chemotherapy, hormonal therapy, interferon, or other biologic response modifiers, prior or concomitant radiation therapy to the primary tumor or to metastatic sites Interventions N=120 surgery plus interferon (immediate radical nephrectomy followed by therapy with interferon alfa-2b) https://web.pathway.md/studies/rec8EX6RZRGJLafFz 1/2 6/29/23, 11:57 PM SWOG 8949 Pathway N=121 interferon treatment alone (immediate interferon alfa-2b therapy without surgery) Primary outcome Survival 11.1 months 11.1 8.3 months 8.1 5.5 months 2.8 months No significant difference 0.0 months Surgery plus interferon Interferon treatment alone No significant difference in survival (11.1 months vs. 8.1 months; AD 3 months, 95% CI -0.01 to 6.01) Secondary outcomes No significant difference in survival with performance status 1 (6.9 months vs. 4.8 months; AD 2.1 months, 95% CI -0.25 to 4.45) Significant increase in survival with lung metastases (14.3 months vs. 10.3 months; AD 4 months, 95% CI 1.04 to 6.96) Conclusion In patients with metastatic renal cell cancer who were acceptable candidates for nephrectomy, surgery plus interferon was superior to interferon treatment alone with respect to survival. Reference Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001 Dec 6;345(23):1655-9. Open reference URL https://web.pathway.md/studies/rec8EX6RZRGJLafFz 2/2